Genfit S.A. (NASDAQ:GNFT – Get Free Report)’s stock price traded down 3.8% during mid-day trading on Wednesday . The company traded as low as $3.77 and last traded at $3.79. 5,525 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 15,876 shares. The stock had previously closed at $3.94.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Genfit in a report on Friday, October 11th.
Read Our Latest Stock Report on Genfit
Genfit Price Performance
About Genfit
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Featured Articles
- Five stocks we like better than Genfit
- Are Penny Stocks a Good Fit for Your Portfolio?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- What is the S&P 500 and How It is Distinct from Other Indexes
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Buy P&G Now, Before It Sets A New All-Time High
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.